로고

Diagnostics and therapeutic solutions
for human healthcare

주요개발성과

> 연구개발 > 주요개발성과

바이오 산업에서 생물체의 유전 정보는 분자 진단 시장을 비롯하여 제약 개발에까지 고부가가치의 정보를 제공함으로써, 이를 활용한 보건의료산업이 급속도로 성장하고 있습니다. 또한 전세계적으로 의료수요자 중심, 비용효용성 중시, 진단 산업 중시 등 보건의료 시스템의 구조적 대변화를 유도하고 있습니다.

바이오산업은 가치사슬의 단계별 비용 비중과 비례하여 시장가치가 증대됩니다. 진매트릭스는 원천기술을 통해 사업화된 제품군의 경쟁력을 강화하고, 향후에도 경쟁력 있는 분자 진단 기반 기술을 지속적으로 개발해나갈 것입니다. 또한 상품 기반 다양화 및 시스템화를 통해 사업 기반을 더욱 공고히 해나가 국제적으로 맞춤의약 분야를 선도해나가는 기업으로서 지속적으로 성장해 나갈 것입니다.


특허


밀순 추출물을 유효성분으로 함유하는 비알코올성 지방간 질환 예방 또는 개선을 위한 조성물 한국특허 출원
유전자 표적부위 염기서열분석방법 한국 특허 등록
재조합 단백질의 가용화를 위한 조성물, 그 방법 및 이를 이용한 재조합 항원의 생산방법 PCT, 한국 특허 출원
절단된 상보적인 태그 절편을 이용한 표적 핵산 서열 검출 및 그 조성물 한국 특허 등록
간세포암 환자의 소라페닙 반응을 예측하는 유전자 마커 및 그 이용 한국 특허 등록
심장형 지방산 결합 단백에 특이적인 단일클론항체와 이를 생산하는 하이브리도마 세포 및 그의 제조방법 한국 특허 등록
DNA 제한효소에 의해 활성조절이 가능한 프라이머 및 이를 이용한 유전자 증폭방법 그리고 이러한 프라이머의 설계법 한국 특허 출원
고위험군 인유두종바이러스 유전자 분석용 키트 및 그 분석방법 한국 특허 출원
만성 B형 간염 치료제의 약제내성 예측용 조성물 및 그 예측 방법 한국 특허 등록
만성B형 간질환 환자의 간세포암 발병위험도 분석 및 예측방법 한국 특허 등록
항암 및 항암 보조제 조성물 한국 특허 등록
RNA변이 분석방법 한국 특허 등록
만성B형 간질환 환자의 간세포암 발병위험도 분석 및 예측방법 한국 특허 등록
밀순 추출물을 유효성분으로 함유하는 비만증의 치료 및 예방을 위한 조성물 한국 특허 등록
표적유전자의 다양한 변이가 존재하는 유전자 영역을 증폭하기 위한 프라이머 조성물 한국,유럽,중국 특허 등록
제한효소절편질량다형성법을 이용한 윌슨병원인유전자변이 검출방법 한국 특허 등록
소맥엽 추출물 또는 이의 분획물을 유효성분으로 함유하는 조성물 한국 특허 등록
톨루엔 흡입여부 진단스트립 및 이를 포함하는 진단키트(특허 제10-1202622호) 한국 특허 등록
톨루엔 흡입여부 진단스트립 및 이를 포함하는 진단키트(특허 제10-1202624호) 한국 특허 등록
다중 염기변이 분석방법 한국 특허 등록
염기변이 분석방법 한국,일본,미국,중국,홍콩 특허 등록
마뇨산 항원에 대한 단일클론 항체 한국,미국 특허 등록
염기변이 분석 프라이머 및 그 방법 한국 특허 등록



논문


1. Kim SH, Hong SP, Cho W, Kim J, Lee TG, Yoon S. Rapid Genotyping of Human Papillomavirus by Desorption Electrospray Ionization Mass Spectrometry. Bull. Korean Chem. Soc. 2017;38(6):603–606.
2. Im JY, Ki HH, Xin M, Kwon SU, Kim YH, Kim DK, Hong SP, Jin JS, Lee YM. Anti-obesity effect of Triticum aestivum sprout extract in high-fat-diet-induced obese mice. Biosci Biotechnol Biochem. 2015;79(7):1133-1140.
3. Chon YE, Jin B, Ahn SH, Kim S, Kim ND, Park JH, Nam CM, Kim KH, Hong SP, Choi SH, Kim DY, Park JY, Han KH. Clonal evolution of multidrug resistant hepatitis B virus during entecavir rescue therapy. Liver Int 2015;35(11):2370-2383.
4. Lee JH, Hong SP, Jang ES, Park SJ, Hwang SG, Kang SK, Jeong SH. Analysis of HBV genotype, drug resistant mutations, and pre-core/basal core promoter mutations in Korean patients with acute hepatitis B. J Med Virol 2015 ;87(6):993-998. 
5. Park BG, Sohn YH, Oh HB, Seo EJ, Jang S, Hong SP. Loss of Mismatched HLA Detected in the Peripheral Blood of an AML Patient who Relapsed After Haploidentical Hematopoietic Stem Cell Transplantation. Ann Lab Med 2015 35(5):551-553. 
6. Yim HJ, Lee HJ, Suh SJ, Seo YS, Kim CW, Lee CD, Park SH, Lee MS, Park CK, Chae HB, Kim MY, Baik SK, Kim YS, Kim JH, Lee JI, Lee JW, Hong SP, Um SH. Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations. Intervirology 2014;57(5):239-247.
7. Choi HS, Min KT, Cha YS, Hong SP. Multiplex detection of KRAS mutations by a matrix-assisted laser desorption/ionization-time of flight mass spectrometry assay. Clin Biochem 2014 ;47(12):1091-1097.
8. Bae JM, Min KT, Shin JY, Shin SK, Kim SN, Lee HP, Kim SO, Hong SP. Comparison of digene hybrid capture 2, GeneMatrix PapilloScreen, and a PCR sequencing assay in detecting high-risk and probable high-risk oncogenic HPV genotypes in specimens from Korean women. Arch Virol 2014;159(8):1909-1916.
9. Chun JY, Shin SK, Min KT, Cho W, Kim J, Kim SO, Hong SP. Performance evaluation of the TheraTyper-GJB2 assay for detection of GJB2 gene mutations. J Mol Diagn 2014 (5):573-83. 
10. Ayres A, Yuen L, Jackson KM, Manoharan S, Glass A, Maley M, Yoo W, Hong SP, Kim SO, Luciani F, Bowden DS, Bayliss J, Levy MT, Locarnini SA. Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations. J Viral Hepat 2014 (11):809-817.  
11. Ahn SH, Chun JY, Shin SK, Park JY, Yoo W, Hong SP, Kim SO,Han KH. Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B. Clin Mol Hepatol 2013;19:399-408.
12. Cho YU, Kim SO, Chi HS, Park SJ, Jang S, Park CJ, Seo EJ, Lee JH, Lee JH, Lee KH, Im HJ, Seo JJ, Hong SP. Detection of ABL1 kinase mutations in Philadelphia-positive patients exhibiting an inadequate molecular response using restriction fragment mass polymorphism and its clinical significance: a single-center experience in Korea. Int J Lab Hematol. 2013;35(6):589-600.
13. Yim HJ, Seo YS, Yoon EL, Kim CW, Lee CD, Park SH, Lee MS, Park CK, Chae HB, Kim MY, Baik SK, Kim YS, Kim JH, Lee JI, Lee JW, Hong SP, Um SH. Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. Liver Int. 2013;33(2):244-254.
14. Lee HP, Cho W, Bae JM, Shin JY, Shin SK, Hwang SY, Min KT, Kim SN, Lee SJ, Kim SO, Yoo WD, Hong SP. Comparison of the clinical performance of restriction fragment mass polymorphism (RFMP) and Roche linear array HPV test assays for HPV detection and genotyping. J Clin Virol. 2013;57(2)130-135.
15. Lee JH, Hachiya A, Shin SK, Lee J, Gatanaga H, Oka S, Kirby KA, Ong YT, Sarafianos SG, Folk WR, Yoo W, Hong SP, Kim SO. Restriction fragment mass polymorphism (RFMP) analysis based on MALDI-TOF mass spectrometry for detecting antiretroviral resistance in HIV-1 infected patients. Clin Microbiol Infect. 2013;19(6)E263-270.
16. Kim SS, Cho SW, Kim SO, Hong SP, Cheong JY. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: Clonal evolution during lamivudine plus adefovir therapy. J Med Virol. 2013;85(1):55-64.
17. Lee SJ, Yim HJ, Hwang SG, Seo YS, Kim JH, Yoon EL, Lee JM, Kim BH, Park SJ, Park YM, Kim HS, Lee SH, Ahn SH, Lee JI, Lee JW, Kim IH, Kim HS, Hong SP. Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study. Scand J Gastroenterol. 2013;482: 196-204.
18. Michailidis E, Singh K, Kirby KA, Hachiya A, Yoo W, Hong SP, Kim SO, Folk WR, Sarafianos SG. Hepatitis B Virus genotypic differences map structurally close to NRTI resistance hot spots. Int J Curr Chem. 2011;2(4):253-260. 
19. Michailidis E, Kirby KA, Hachiya A, Yoo W, Hong SP, Kim SO, Folk WR, Sarafianos SG. Antiviral therapies: Focus on hepatitis B reverse transcriptase. Int J Biochem Cell Biol. 2012;44(7):1060-1071.
20. Lee HW, Kim HJ, Hong SP, Cha BK, Chang HY, Choi CH, Do JH, Kim JG, Chang SK.Simultaneous emergence of entecavir resistance mutations in a nucleoside-naive chronic hepatitis B patient. Intervirology. 2012;55(5):380-384.
21. Kim SS, Cheong JY, Lee D, Lee MH, Hong SP, Kim SO, Cho SW. Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B. J Med Virol. 2012;84(1):18-25
22. Jang JW, Chun JY, Park YM, Shin SK, Yoo W, Kim SO, Hong SP. Mutational complex genotype of the hepatitis B virus X /precore regions as a novel predictive marker for hepatocellular carcinoma. Cancer Sci. 2011;103(2):296-304
23. Hong SP. Monitoring of hepatitis B: Detection of drug resistance. Korean J Hepatol. 2011;17(4S):22-37.
24. Cha YS, Choi SH, Lee JH, Shin SK, Lee SH, Lee SD, Kim SO, Hong SP. Analysis of TPOX short tandem repeat locus with matrix-associated laser desorption/ionization time-of-flight-based restriction fragment mass polymorphism assay. Anal Biochem 2011 ;412(1):79-84.
25. Lee HP, Kim SO, Hwang TS, Bae JM, Kim SN, Kim JW, Hwang SY, Lee HS, Shin SK, Cho W, Hong SP. Analytical and clinical performances of a restriction fragment mass polymorphism assay for detection and genotyping of a wide spectrum of human papillomaviruses. J Med Virol 2011 ;83(3):471-82. 
26. Han KH*, Hong SP*, Choi SH, Shin SK, Cho SW, Ahn SH, Hahn JS, Kim SO. Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B. Antiviral Therapy 2011;16(1):77-87. * Equal contribution
27. Jung YK, Yeon JE, Han WS, Kim JH, Kim JH, Park JJ, Kim JS, Bak YT, Yoo W, Hong SP, Kim SO, Kwon SY, Byun KS, Lee CH. Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated Lamivudine-resistant chronic hepatitis B. Gut Liver. 2010;4(2):212-8. 
28. Oh YJ, Park YM, Hong SP, Shin SK, Ji SI, Kim BH, Park SJ, Hong Z. A YIDD Mutation in a Case of Recurrent Hepatitis B after Liver Transplantation Induced by an S-escape Mutant. Gut Liver. 2010;4(2):253-7. 
29. Kim BU, Goo JC, Park BC, Kim SO, Hong SP, Jeong JI, Chae HB, Park SM, Youn SJ. Genotypic resistance to entecavir in chronic hepatitis B patients. Korean J Hepatol. 2010;16(2):147-57. 
30. Song J, Kim OJ, Km HS, Bae SJ, Hong SP, Oh DY, Kim NK. Endothelial nitric oxide synthase gene polymorphisms and the risk of silent brain infarction. Int J Mol Med 2010;25:819-823.
31. Lee JM, Park JY, Lee CK, Kim DY, Nguyen T, Hong SP, Kim SO, Chon JY, Han KH, Ahn SH. Long term adefovir dipivoxil monotherapy for up to 5 years in lamivudine resistant chronic hepatitis B. Antiviral Therapy 2010;15-235-241.
32. Han IB, Kim OJ, Ahn JY, Oh D, Hong SP, Huh R, Chung SS, Kim NK. Association of Methylenetetrahydrofolate Reductase (MTHFR 677C>T and 1298A>C) Polymorphisms and Haplotypes with Silent Brain Infarction and Homocysteine Levels in a Korean Population. Yonsei Med J 2010;51(2):253-260.
33. Choe WH, Hong SP, Kim BK, Ko SY, Jung YK, Kim JH, Yeon JE, Byun KS, Kim KH, Ji SI, Kim SO, Lee CH, Kwon SY. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. Antiviral Therapy 2009;14:985-993. 
34. Lee JM, Kim HJ, Park JY, Lee CK, Kim DY, Kim JK, Lee HW, Pail YH, Lee KS, Han KH, Chon JY, Hong SP, Nguyen T. Rescue Monotherapy in Lamivudine-Resistant HBeAg Positive Chronic Hepatitis B: Adefovir Versus Entecavir. Antiviral Therapy 2009 ;14:705-712.
35. Cho SW, Koh JY, Cheong JY, Lee MH, Hong SP, Yoo W, Kim SO. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance. J Viral Hepatitis 2010;17:171-177. 
36. Kwon HC, Cheong JY, Cho SW, Choi JM, Hong SP, Kim SO, Yoo WD. Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy. J Gastroenterol Hepatol. 2009 ;24:49-54.
37. Cha CK, Kwon HC, Cheong JY, Cho SW, Hong SP, Kim SO, Yoo WD. Association of Lamivudine-Resistant Mutational Patterns with Antiviral Effect of Adefovir in Patients with Chronic Hepatitis B. J Med Virol 2009; 81(3):417-424.
38. Hong SP, Shin SG, Lee EH, Chung HJ, Park SN, Yoo WD, Folk WR, Kim SO. High-resolution virus genotyping by MALDI-TOF mass spectrometry. Nature Protocols 2008; 3(9):1476-1484. 
39. Hong SP, Chung HJ, Lee HS, Lee SH, Lee SD, Oh HB, Kim WK, Song JH, Yoo WD, Folk WR, Kim SO. A Simple and Accurate Genotyping Strategy Based on TypeIIS Restriction Endonuclease Cleavage and Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry. BMC Genomics 2008;9:276-285. 
40. Kwon CI, Hwang SG, Shin SJ, Chang SW, Kim SY, Ko KH, Hong SP, Park PW, Rim KS, Kang MS, Chung HJ, Hong SP. Occult hepatitis B virus infection in pregnant woman and its clinical implication. Liver Int. 2008;28(5):667-674.
41. Cheong JY, Cho SW, Yoo JH, Hong SP, Kim SO, Yoo WD, Kim JH. Selection of Precore Mutants during Lamivudine Treatment in Patients with Chronic Hepatitis B. Hepato-gastroenterology 2008:55;1029-1033. 
42. Lee EH, Lee KB, Kim EO, Shin SK, Lee HS, Shim SY, Kim SO, Hong SP. Clinical Effectiveness of Restriction Fragment Mass Polymorphism assay for human papillomavirus genotyping. J Lab Med Qual Assur 2008 ;30(2):291-9.
43. Kim SO, Oh HB, Jun KR, Hwang SH, Cha CH, Kim KM, Folk WR, Hong SP, Suh DJ. Hepatitis C Virus Genotype 6 Variant Identified in Korea by analysis of 5' Untranslated Region Using a Matrix Assisted Laser Desorption/Ionization Time of flight -based Assay, Restriction Fragment Mass Polymorphism. J Med Virol 2008;80(10): 1712-1719.  
44. Cho JH, Cheong JY, Kang JK, Park JS, Lee MH, Lim NK, Hong SP, Kim SO, Yoo WD, Cho SW. Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients. Korean J Hepatol. 2008;14(1):58-66.
45. Lee HW, Lee JI, Um SH, Ahn SH, Chang HY, Park YK, Hong SP, Moon YM, Han KH. Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study. J Gastroenterol Hepatol. 2008;(5):729-735.
46. Hwang SH, Oh HB, Choi SE, Hong SP, Yoo W. Effective Screening of Informative Single Nucleotide Polymorphisms using the Novel Method of Restriction Fragment Mass Polymorphism.   Journal of International Medical Research 2007;35: 827-835. 
47. Kim OJ*, Hong SP*, Ahn JY, Hong SH, Hwang TS, Kim SO, Yoo W, Oh DH, Kim NK. Influence of Combined Methionine Synthase (MTR 2756A>G) and Methylenetetrahydrofolate Reductase (MTHFR 677C>T) Polymorphisms to Plasma Homocysteine Levels in Korean Patients with Ischemic Stroke. Yonsei Med J 2007;48:201-209. * Equal contribution
48. Yim HJ, Myun KS, Chang YJ, Suh YS, Yeon JE, Lee CH. Kwon JA, Yoo W, Kim SO, Hong SP. The Levels of Hepatitis B Virus Replication during Non-replicative Phase - HBV Quantification by Real Time PCR in Korea. Digestive Diseases and Science. 2007;52:2403-2409.
49. Sohn SK, Moon JH, Cho YY, Chae YS, Kim JG, Lee KS, Hong SP, Kim SO. Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance. Leuk Lymphoma 2007;48(98):1659-1661.
50. Lee EH, Chung HJ, Oh HB, Chi HS, Jee MS, Park SN, Hong SP, Yoo W, Kim SO.  Human Papilloma Virus Genotyping Assay using Restriction Fragment Mass Polymorphism Analysis, and Its Comparison with Sequencing and Hybrid Capture Assays. Korean J Lab Med 2007;27:62-68.
51. Chung HJ, Kim SN, Lee EH, Jee MS, Kim MA, Hwang SY, Cho HJ, Kim SO, Hong SP. Comparison of Efficacy of Human Papilloma Virus Genotyping Assays using Restriction Fragment Mass Polymorphism and DNA Chip Analysis in Patients with Abnormal Pap Smear and Uterine Cervical Cancer. The Korean Journal of Pathology 2006; 40: 439-47.
52. Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HJ, Chung YH, Lee YS, Yoo WD, Kim SO. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006;43:1385-1391.
53. Ahn SH, Kim DY, Chang HY, Hong SP, Shin JS, Kim YS, Kim H, Paik YH, Lee KS, Chon CY, Moon YM, Han KH. Association of Genetic Variations in CCR5 and Its Ligand, RANTES with Clearance of Hepatitis B Virus in Korea. Journal of Medial Virology. 2006;78(12):1564-1571.
54. Paik YH, Han KH, Hong SP, Lee HW, Lee KS, Kim SO, Shin JE, Ahn SH, Chon CY, Moon YM. Clinical impact of early detection for YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B. Antiviral Therapy. 2006. 11:447-455.
55. Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, Seo YS, Chung HJ, Moon MS, Kim SO, Byun KS, Lee CH. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006. 55(10):1488-95. 
56. Lee CH, Kim SO, Byun KS, Moon MS, Kim EO, Yeon JE, Yoo W, Hong SP. Predominance of Hepatitis B Virus YMDD Mutants is Prognostic of Viral DNA Breakthrough. Gatroenterology 2006; 130(4)1144-1152 
57.  Chung HJ, Yang JH, Hwang SH, Hong SP, Oh HB. The Comparison of Restriction Fragment Mass Polymorphism with Sequencing Method for the Hepatitis C Virus Genotyping. Korean J. Lab. Med. 2005; 25(5): 352-360.
58.  Kim YJ, Kim SO, Chung HJ, Jee MS, Kim BG, Kim KM, Yoon JH, Lee HS, Kim CY, Kim S, Yoo W, Hong SP.  Population Genotyping of Hepatitis C Virus by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Analysis of Short DNA Fragments. Clin. Chem. 2005;51(7):1123-1131 9; Cover Article of the Month, Co-publicated with Editorial; Cook L., Jerome KR. Mass Spectrometry for Genotyping Hepatitis C Virus: A Promising New Approach. Clinical Chemistry 2005;51(7):1091-1092.
59. Kim HS, Han KH, Ahn SH, Kim EO, Chang HY, Moon MS, Chung HJ, Yoo W, Kim SO, Hong SP. Evaluation of Methods for Monitoring Drug Resistance in Chronic Hepatitis B Patients during Lamivudine Therapy Based on Mass Spectrometry and Reverse Hybridization. Antiviral Therapy 2005;11:421-429. 
60. Byon SH, Oh HS, Ahn BY, Hong SP, Kim JK, Kwon OW. Single Nucleotide Polymorphisms in the 3'-untranslated region of Vascular Endothelial Growth Factor in Diabetic Retinopathy. Korean J Ophthalmology 2005;46(11): 1911-1918. 
61. Chang HY, Ahn SH, Kim do Y, Shin JS, Kim YS, Hong SP, Chung HJ, Kim SO, Yoo WD, Han KH. Association between CCR5 Promoter Polymorphisms and Hepatitis B Virus Infection. Korean J Hepatol. 2005 11(2):116-24.
62.  Kim OJ, Hong SP, Yim DJ, Kim HS, Kim WC, Ahn JY, Cho HJ, Hwang SG, Oh D, Kim NK. Thymidylate synthase enhancer region (TSER) polymorphism is a novel genetic determinant of hyperhomocysteinemia in ischemic stroke patients. Korean J Thrombo Hemostat 2004;11:11-18. 
63. Lee JM, Ahn SH, Chang HY, Shin JE, Kim DY, Sim MK, Hong SP, Chung HJ, Kim SO, Han KH, Chon JY, Moon YM. Reappraisal of HBV Genotype and Clinical Significance in Korea Using MALDI-TOF Mass Spectrometry. Korean J. Hepatol. 2004;10(4): 260-270. 
64. Sohn YH, Yoo SJ, Ynag JH, Hwang SH, Hong SP, Oh HB.  The Comparison of Restriction Fragment Mass Polymorphism Method with Sequecing Method for the Detection of HBV YMDD Mutants. Korean J. Lab. Med. 2004; 24: 71-77. 
65. Hong SP, Kim NK, Hwang SG, Chung HJ, Kim S, Han JH, Kim HT, Rim KS, Kang MS, Yoo W, Kim SO. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J. Hepatol. 2004;40(5): 837-844. 
66.  Hong SP. Lamivudine resistance of hepatitis B virus: Mechanism and diagnosis. Korean J. Hepatol. 2003;9(S2):5-10. (review)
67. Kim NK, Hwang SG, Hong SP, Rhee HS, Chung HJ, Han JH, Kim HT, Rim KS, Yoo W, Kim SO. Novel mass spectrometric assay for monitoring drug resistance in hepatitis B virus during lamivudine therapy. Korean J. Genetics 2003;25 (1): 63-75. 
68. Hong SP, Yoo W, Putnak E, Eckels KE, Rho HM, Kim SO. Nucleotide sequence of envelope protein of Japanese encephalitis virus SA14-14-2 adapted to Vero cells. DNA Sequence 2001;12:427-432.
69. Hong SP, Yoo WD, Putnak R, Srivastava AK, Eckels KH, Chung YJ, Rho HM, Kim SO. Preparation of a Purified, Inactivated Japanese Encephalitis (JE) Virus Vaccine in Vero Cells. Biotech. Letters 2001;23(19):1565-1573.
70. Srivastava AK., Putnak JR, Lee SH, Hong SP, Moon SB, Barvir DA, Zhao B, Olason RA, Kim S.O. Yoo W.D. Towle A.C., Vaughn D.W, Innis B.L. and Eckels K.E. Purified, Inactivated Japanese Encephalitis Vaccine made in Vero Cells. Vaccine 2001;19(31): 4557-4565.